Arab L, Anthony MS, McKenzie DC, Hartline HL, Prentice E. Web-based multimedia dietary assessment tool for nutritional research. FASEB J. 2002;16 (5 Pt 1):A383.
Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis. 2002;163(1):183-92.
Mikkola TS, Anthony MS, Clarkson TB, St Clair RW. Cholesterol efflux potential of serum from atherogenic diet-fed cynomolgus monkeys after long-term tibolone treatment or traditional hormone replacement therapy. FASEB J. 2001;15(4):A248.
Cline JM, Anthony MS, Register TC, Borgerink H, Clarkson TB. Tibolone does not stimulate the endometrium or breast in cynomolgus monkeys. FASEB J. 2001;15(4):A594.
Shadoan MK, Rankin SE, Anthony MS, Clarkson TB, Wagner JD. Tibolone increases lean mass and bone mineral density in cynomolgus monkeys. FASEB J. 2001;15(4):A595.
Hannah JS, Yamane K, Kataoka S, Anthony MS, Howard BV. High fat, high cholesterol diets alter low density lipoprotein size and binding affinity in monkeys. Atherosclerosis. 1997 Jul 11;132(1):19-27.
Anthony MS, Pan Y-L, Hughes C, Bullock B, Clarkson TB. Hybrid hamsters as a model for estrogen effects on brain biomarkers. FASEB J. 1997 Feb;11:A107.
Brosnihan KB, Weddle D, Anthony MS, Heise CM, Ferrario CM. Chronic estrogen or estrogen and progestin replacement on the renin-angiotensin system in ovariectomized cynomolgus monkeys. FASEB J. 1995;9:A51.
Wang C-S, Weingand KW, Anthony MS. Effect of atherogenic diet on lipoprotein lipase activity in cynomolgus monkeys. Atherosclerosis. 1987 Oct;67(2-3):173-80.